> ## Documentation Index
> Fetch the complete documentation index at: https://docs.hi-doctor.ai/llms.txt
> Use this file to discover all available pages before exploring further.

# Regaine

> Regaine (minoxidil) is EU-authorised as a topical foam for hair loss. The tablet form is only licensed for blood pressure — hair use is off-label.

Minoxidil comes in two very different forms sold under the Regaine brand,
and the difference matters. The liquid or foam rubbed into the scalp is a
properly authorised medicine for male pattern hair loss in EU countries.
Minoxidil also exists as a tablet, but in the EU those tablets are licensed
only as a blood-pressure medicine — taking low-dose minoxidil tablets for
hair is off-label.

<Info>
  Active ingredient: **minoxidil** · Dosages: **5% topical** · **2.5–5 mg
  oral** (off-label) · Indicated for androgenetic alopecia (pattern hair
  loss) in adult men
</Info>

## What it is

<Tabs>
  <Tab title="Topical foam or solution">
    An EU-authorised medicine for male pattern hair loss, sold both on
    prescription and over the counter. This is the form the hair-loss
    evidence below is based on.
  </Tab>

  <Tab title="Oral tablet">
    In the EU, minoxidil tablets are licensed only as a blood-pressure
    medicine for severe resistant hypertension. Taking low-dose tablets for
    hair is off-label — a doctor prescribing outside the licensed use.
  </Tab>
</Tabs>

Regaine holds national authorisations rather than a single centralised EU
one. Topical minoxidil has been authorised for use in Spain since 1 May
1988 for moderate androgenetic alopecia. The Spanish Regaine foam
(50 mg/g) is sold without a prescription. In the United Kingdom, McNeil
Products Limited holds a wider Regaine range: 5% scalp foam and 5% scalp
solution for men, plus a 5% foam and a regular-strength solution for women
aged 18 to 65. Rogaine is the same product under its United States name.

## How it works

<CardGroup cols={3}>
  <Card title="Minoxidil opens potassium channels" icon="atom">
    Applied to the scalp, minoxidil acts on ATP-sensitive potassium
    channels.
  </Card>

  <Card title="Blood flow around follicles rises" icon="droplet">
    This widens small blood vessels around the hair follicle.
  </Card>

  <Card title="The growing phase lasts longer" icon="seedling">
    Minoxidil appears to keep hair follicles in their growing (anagen)
    phase for longer and increases hair diameter, although exactly how it
    acts on hair is still not fully understood.
  </Card>
</CardGroup>

## What the studies reported

<Note>
  Results are grouped by source and evidence grade so journal data and
  manufacturer announcements cannot be confused.
</Note>

The main topical trial ran for 48 weeks in men aged 18–49 with
vertex-pattern hair loss, so it does not establish results beyond one year
or in other patterns of hair loss (Olsen et al., *J Am Acad Dermatol*
2002\).

## What has been reported

**Topical minoxidil**, per the EU product information:

| Effect                                                                   | Frequency                                                                    |
| ------------------------------------------------------------------------ | ---------------------------------------------------------------------------- |
| Itching, dermatitis, acneiform dermatitis, rash                          | Common (occasionally more severe: peeling, blistering, bleeding, ulceration) |
| Unwanted hair growth away from the scalp, including facial hair in women | Common                                                                       |
| Headache, breathlessness (dyspnoea)                                      | Common                                                                       |
| Dizziness, nausea, peripheral oedema                                     | Uncommon                                                                     |
| Palpitations, tachycardia, chest pain                                    | Rare                                                                         |
| Low blood pressure, allergic reactions including angioedema              | Not known                                                                    |
| Temporary increased shedding                                             | Not known                                                                    |

**Off-label oral minoxidil**, from a 24-week randomised trial of oral
minoxidil 5 mg vs topical minoxidil 5% (n=45 per arm):

| Effect         | Oral 5 mg   | Topical 5%                              |
| -------------- | ----------- | --------------------------------------- |
| Hypertrichosis | 49% (22/45) | 25% (11/45) — P=.02                     |
| Headache       | 14% (6/45)  | 2% (1/45) — P=.046                      |
| Scalp eczema   | 2% (1/45)   | 16% (7/45) — more frequent with topical |

A separate retrospective study of 1,404 patients treated with off-label
oral minoxidil for at least 3 months found hypertrichosis in 15.1%
(causing withdrawal in 0.5%), lightheadedness in 1.7%, fluid retention in
1.3%, tachycardia in 0.9%, headache in 0.4%, periorbital oedema in 0.3% and
insomnia in 0.2% — leading to discontinuation in 1.2% of patients overall.

<Warning>
  EU-authorised oral minoxidil tablets are indicated only for severe
  resistant hypertension, and their product information states they must
  never be used alone or as initial therapy — always alongside a beta-blocker
  and a diuretic, and with warnings about fluid retention and fluid around
  the heart. None of that licensed dosing framework applies to the low doses
  used off-label for hair loss.
</Warning>

## Common questions

<AccordionGroup>
  <Accordion title="Does Regaine work for women?" icon="person-dress">
    Regaine foam 5% and a regular-strength solution are authorised for women aged 18 to 65 in the United Kingdom. In Spain, Regaine foam (50 mg/g) is indicated for androgenetic alopecia in adult men. For women, the doctor may consider off-label options including oral minoxidil under medical supervision.
  </Accordion>

  <Accordion title="How long does Regaine take to work?" icon="clock">
    The main topical trial ran for 48 weeks in men aged 18–49 with vertex-pattern hair loss. Visible results take months — maximum visible results come at 6–12 months. Consistent daily use is needed before judging effectiveness. Photographs taken in the same light are more useful than day-to-day checking.
  </Accordion>

  <Accordion title="What is the difference between Regaine foam and solution?" icon="spray-can">
    Regaine is available as a 5% scalp foam and a 5% scalp solution. Both contain minoxidil as the active ingredient. The foam dries faster and may be easier to apply. The choice between them depends on personal preference and scalp tolerance.
  </Accordion>

  <Accordion title="Can I take oral Regaine tablets for hair loss?" icon="pills">
    In the EU, minoxidil tablets are licensed only as a blood-pressure medicine for severe resistant hypertension. Taking low-dose tablets for hair is off-label — a doctor prescribing outside the licensed use. Off-label oral minoxidil requires close medical supervision for potential cardiovascular effects.
  </Accordion>

  <Accordion title="What causes the temporary increased shedding with Regaine?" icon="scissors">
    A temporary increase in shedding can occur when starting topical minoxidil. This is the hair follicle transitioning from resting to growing phase, and it does not predict the final outcome. Shedding usually settles within weeks as new growth begins.
  </Accordion>

  <Accordion title="Can I use Regaine with finasteride?" icon="pills">
    Yes. Minoxidil combines well with finasteride or dutasteride. The two medicines work through different mechanisms — finasteride blocks DHT production while minoxidil stimulates the follicle — and a doctor may prescribe them together for a better response.
  </Accordion>

  <Accordion title="What is the difference between Regaine and Rogaine?" icon="question">
    Regaine and Rogaine are the same product under different brand names. Rogaine is the name used in the United States. Both contain minoxidil as the active ingredient in the same concentrations.
  </Accordion>
</AccordionGroup>

## How Hi-Doctor handles it

Topical minoxidil or off-label oral minoxidil, depending on your case.
Minoxidil combines well with finasteride or [dutasteride](/library/medicines/dutasteride).
An EU-licensed doctor reviews your case and, if eligible, issues an
electronic prescription valid at any EU pharmacy under Directive
2011/24/EU. Applied to a dry scalp, topical minoxidil is typically used
twice a day; tablets, if prescribed, once daily. See [how a consultation
works](/essentials/how-it-works), the [treatment areas](/essentials/treatments)
Hi-Doctor covers, [pricing](/essentials/pricing), and eligibility checks in
[safety](/essentials/safety).

## Sources

* AEMPS CIMA — Regaxidil 20 mg/ml solución cutánea, ficha técnica (Spain,
  registration 57597, authorised 1 May 1988) — indicated for moderate
  androgenetic alopecia
* AEMPS CIMA — Regaine 50 mg/g espuma cutánea, ficha técnica (Spain,
  registration 76483) — indicated for androgenetic alopecia in adult men
* AEMPS CIMA — Loniten 10 mg comprimidos, ficha técnica (Spain,
  registration 55636) — oral minoxidil, indicated for severe hypertension
  only
* AEMPS CIMA — Minogal 2,5/5/10 mg comprimidos EFG, ficha técnica (Spain,
  registration 91045-91047, authorised 2026) — oral minoxidil, indicated
  for severe resistant hypertension only
* Olsen et al., *J Am Acad Dermatol* 2002;47(3):377-385 (PMID 12196747)
* Penha MA, Miot HA, Kasprzak M, Muller Ramos P. Oral minoxidil vs topical
  minoxidil for male androgenetic alopecia: a randomized clinical trial.
  *JAMA Dermatol*. 2024;160(6):600-605 (PMID 38598226)
* Vaño-Gálvan S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose
  oral minoxidil for hair loss: a multicenter study of 1,404 patients.
  *J Am Acad Dermatol*. 2021;84(6):1644-1651 (PMID 33639244)
* Rodrigues Dias F, Yong SS, FitzGerald H, Sinclair RD, Bhoyrul B.
  Expanding the therapeutic landscape of minoxidil for androgenetic
  alopecia. *Front Pharmacol*. 2026;16:1718208 — reproduces the Olsen 2002
  hair-count figures and states oral minoxidil is not formally approved
  for androgenetic alopecia

## Start a consultation

<Card title="Hair-growth consultation" icon="stethoscope" href="https://hi-doctor.ai/consultation/hair-growth/1">
  Answer the hair-growth questionnaire and a registered doctor reviews it.
  They decide whether treatment is appropriate, which one, and at what dose —
  and declining is a normal outcome. See [what it costs](/essentials/pricing)
  and [how the review works](/essentials/how-it-works).
</Card>

<Warning>
  This page is reference information, not medical advice and not a prescription.
  Whether a medicine is appropriate for you is decided by a registered doctor
  after reviewing your consultation.
</Warning>